ClinicalTrials.Veeva

Menu

Characterization and Pathogenesis of ACLF (ACLF-I)

J

Johann Wolfgang Goethe University Hospital

Status

Enrolling

Conditions

Acute-On-Chronic Liver Failure
Portal Hypertension
Liver Cirrhosis

Study type

Observational

Funder types

Other

Identifiers

NCT04975490
ACLF-Initiative

Details and patient eligibility

About

This single-center prospective observational study aims at characterization of pathogenesis of ACLF. There will be three different cohorts investigated with the main endpoint mortality in these groups.

  1. SAPIENT = Sepsis ACLF patients, to investigate the differences between ACLF and sepsis in cirrhosis
  2. PROACT = Portal mediators as ACLF Targets, to assess portal venous biomarkers in patients receiving TIPS leading to ACLF and identify potential treatment targets
  3. ELITE = prEdictors of beneficial LIver Tx in ACFL patiEnts, to assess in ACLF-patients receiving liver transplantation predictors of survival, which may improve selection of ACLF-patients for liver transplantation Secondary endpoints will be different in the three different cohorts and biological material will be collected for separate ancillary studies.

Enrollment

1,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Liver cirrhosis

Exclusion criteria

  • extrahepatic and metastatic malignancy,
  • refusal for participation
  • decision of attending phycisian

Trial design

1,000 participants in 3 patient groups

SAPIENT = Sepsis ACLF patients
PROACT = Portal mediators as ACLF Targets
ELITE = prEdictors of beneficial LIver Tx in ACFL patiEnts

Trial contacts and locations

1

Loading...

Central trial contact

Jonel Trebicka, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems